全文获取类型
收费全文 | 7324篇 |
免费 | 872篇 |
国内免费 | 276篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 255篇 |
妇产科学 | 37篇 |
基础医学 | 2119篇 |
口腔科学 | 27篇 |
临床医学 | 672篇 |
内科学 | 871篇 |
皮肤病学 | 168篇 |
神经病学 | 102篇 |
特种医学 | 57篇 |
外国民族医学 | 3篇 |
外科学 | 405篇 |
综合类 | 552篇 |
现状与发展 | 8篇 |
预防医学 | 122篇 |
眼科学 | 25篇 |
药学 | 625篇 |
2篇 | |
中国医学 | 22篇 |
肿瘤学 | 2316篇 |
出版年
2024年 | 56篇 |
2023年 | 289篇 |
2022年 | 491篇 |
2021年 | 595篇 |
2020年 | 507篇 |
2019年 | 427篇 |
2018年 | 411篇 |
2017年 | 367篇 |
2016年 | 338篇 |
2015年 | 284篇 |
2014年 | 334篇 |
2013年 | 843篇 |
2012年 | 271篇 |
2011年 | 324篇 |
2010年 | 243篇 |
2009年 | 223篇 |
2008年 | 234篇 |
2007年 | 217篇 |
2006年 | 231篇 |
2005年 | 185篇 |
2004年 | 204篇 |
2003年 | 158篇 |
2002年 | 149篇 |
2001年 | 156篇 |
2000年 | 108篇 |
1999年 | 100篇 |
1998年 | 83篇 |
1997年 | 85篇 |
1996年 | 88篇 |
1995年 | 67篇 |
1994年 | 55篇 |
1993年 | 43篇 |
1992年 | 34篇 |
1991年 | 35篇 |
1990年 | 31篇 |
1989年 | 20篇 |
1988年 | 24篇 |
1987年 | 13篇 |
1986年 | 19篇 |
1985年 | 19篇 |
1984年 | 26篇 |
1983年 | 13篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 10篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1972年 | 1篇 |
排序方式: 共有8472条查询结果,搜索用时 31 毫秒
11.
12.
WT1基因位于人类染色体11p13,在80%的急性髓系白血病(acute myeloid leukemia,AML)患者中高表达,是AML预后不良的分子标志,可作为AML预后评估和微小残留病变(minimal residual disease,MRD)监测的有效指标。由于WT1在AML中均有异常高表达,故认为是一种AML抗原,可作为特异性免疫治疗的新靶点。一些小规模的临床试验证实以WT1为靶点的免疫治疗是有效的、安全的,这些免疫治疗可作为那些有高危复发风险及初始标准化疗失败的AML患者的辅助治疗。本文就近几年WT1与AML的预后及有关以WT1为靶点的主动特异性免疫治疗的研究进展予以综述。 相似文献
13.
Özlem Keskin Ayfer Tuncer Gonul Adalioglu Bulent E. Sekerel Cansn Saçkesen Omer Kalayc 《Pediatric allergy and immunology》2006,17(6):396-407
Allergoid immunotherapy is a new form of allergen immunotherapy allowing safe administration of high allergen doses. There is limited information on the effects of allergoid immunotherapy in children with allergic rhinitis. To investigate the immunological and clinical effects of allergoid immunotherapy in children with allergic rhinitis due to grass pollen allergy. Children with allergic rhinitis were assigned to allergoid immunotherapy (n = 27) or control (n = 26, no immunotherapy) groups. Children in the immunotherapy group received seven injections of grass pollen allergoid immunotherapy before grass pollen season and continued to receive maintenance immunotherapy for 27 months. All patients were offered a pharmacotherapy regimen to be used on demand during the pollen seasons. Clinical and laboratory parameters were compared between the immunotherapy and control groups. The rhinoconjunctivitis symptom-medication score and asthma symptom score were lower in the immunotherapy group after 1 yr of maintenance immunotherapy (p < 0.01 for both). Skin test reactivity and nasal reactivity as determined by nasal provocation testing for grass pollen were significantly decreased after 1 yr of immunotherapy (p < 0.001 for both). The seasonal increase in bronchial reactivity and nasal lavage eosinophil cationic protein levels were prevented after the first year of immunotherapy (p < 0.05 for both). The seasonal increase in immunoglobulin (Ig)E decreased (p < 0.05) and grass-specific IgG, IgG(1) and IgG(4) increased significantly already at the end of the seven-injection build-up therapy (p < 0.001, for all). Interleukin (IL)-4 levels in the culture supernatants showed a steady decline from baseline at first and second year of immunotherapy (p < 0.001) but remained unchanged in the control group. Allergoid immunotherapy is an effective method in the treatment of grass pollen-induced allergic rhinitis in children and prevents the seasonal increase in bronchial hyper-reactivity. Changes in specific IgE and IgG levels and decreased IL-4 production in peripheral blood mononuclear cell culture supernatants may account for the observed clinical effects. 相似文献
14.
15.
目的:制备高表达GM-CSF的淋巴瘤细胞系,观察淋巴瘤细胞转染GM-CSF基因后生物学特性的改变。方法:将小鼠GF-CSF真核表达质粒用电穿孔法导入小鼠淋巴瘤细胞系RMA,有限稀释法制备单个细胞克隆,经RT-PCR,骨髓祖细胞增殖实验和集落形成实验筛选相对高表达GM-CSF的RMA克隆,并观察其生物学特性的改变。结果:获得了高表达GM-CS的RMA细胞系,其同基因动物体内致瘤性降低。结论:淋巴瘤细胞系RMA转染GM-CSF基因后致瘤性降低。 相似文献
16.
T. Saarne L. Kaiser H. Grönlund O. Rasool G. Gafvelin M. van Hage-Hamsten 《Clinical and experimental allergy》2005,35(5):657-663
BACKGROUND: Allergen-specific immunotherapy is the only treatment for allergic disease providing long-lasting symptom relief. Currently, it is mainly based on the use of crude allergen extracts. The treatment may be improved by the use of genetically engineered allergens, hypoallergens, aiming at a more effective and safer therapy. OBJECTIVE: The aim of this study was to provide a rational design of hypoallergen candidates for immunotherapy by using structural information and knowledge of B and T cell epitopes of an allergen. METHODS: The three-dimensional structure of the major cat allergen Fel d 1 was systematically altered by duplication of selected T cell epitopes and disruption of disulphide bonds. Seven Fel d 1 derivatives were generated and screened for allergenic reactivity in comparison with recombinant Fel d 1 in competition-ELISA. The allergenicity was further evaluated in basophil activation experiments and T cell reactivity was assessed in a lymphoproliferation assay. RESULTS: Three out of seven Fel d 1 derivatives, with two duplicated T cell epitopes and one or two disulphide bonds disrupted, were carefully evaluated. The three derivatives displayed a strong reduction in allergenicity with 400-900 times lower IgE-binding capacity than recombinant Fel d 1. In addition, they induced a lower degree of basophil activation and similar or stronger T cell proliferation than recombinant Fel d 1. CONCLUSION: By a rational approach, we have constructed three Fel d 1 hypoallergens with reduced IgE-binding capacities and retained T cell reactivities. This strategy may be applied to any well-characterized allergen to improve immunotherapy for allergic patients. 相似文献
17.
Giorgio Ciprandi Mara De Amici Simone Negrini Gianluigi Marseglia Maria Angela Tosca 《International immunopharmacology》2009,9(10):1247-1249
Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels. 相似文献
18.
Yasuyo Shintani Yoshihisa Sawada Takeshi Inagaki Yasuo Kohjimoto Yasunari Uekado Toshiaki Shinka 《International journal of urology》2007,14(2):140-146
AIM: In order to clarify the initial step of the mechanism by which bacillus Calmette-Guérin (BCG) exhibits antitumor activity via the immune response induced in the bladder submucosa after intravesical BCG therapy for human bladder cancer, various cytokines secreted in the urine after BCG instillation were measured. METHODS: After transurethral resection of bladder cancer, a 6-week course of BCG instillation was performed. At the first and sixth weeks' dosings, spontaneously excreted urine was collected before and 4, 8, and 24 h after BCG instillation. The urinary cytokines were determined by Sandwich enzyme-linked immunosorbent assay using monoclonal antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-1beta, IL-8, interferon (IFN)-gamma, and IL-12. RESULTS: After the BCG therapy, various cytokines, such as GM-CSF, TNF-alpha, G-CSF, IL-1beta, IL-8, IFN-gamma, and IL-12 were secreted, comprising the immune response cascade. The mean urinary excretions of GM-CSF and TNF-alpha 4 h after the sixth week's instillation were significantly higher than the pre-instillation levels. There were no significant increases in the urinary IFN-gamma or IL-12 levels between 4 and 24 h after the sixth week's instillation. The TNF-alpha level 4 h after the sixth week's instillation had a strong tendency towards the absence of recurrence, with a mean follow-up of 54.1 months. The Kaplan-Meier curve showed the 2, 5, and 10-year recurrence-free survival rates were 72.4%, 65.8%, and 56.4%, respectively. CONCLUSIONS: We suggested that the urinary levels of TNF-alpha might be essential in antitumor activity after BCG therapy and might play an important role in the prevention of bladder tumor recurrence. 相似文献
19.
C Diaz-Sarrio† N Salvatella-Danés† M Castro-Forns‡ A Nadal§ 《Journal of the European Academy of Dermatology and Venereology》2007,21(7):973-976
Langerhans cell sarcoma is a rare, aggressive tumour that may metastasize to many organs, likely leading to death of the patient within 1 year. We present the first case described in the literature in a patient who underwent transplantation. 相似文献
20.
目的观察比较泼尼松联用硫唑嘌呤和大剂量静脉用免疫球蛋白(IVIG)对扩张型心肌病(DCM)患儿心功能及预后的影响。方法将DCM患儿20例分为治疗Ⅰ和Ⅱ组,分别在传统抗心衰治疗基础上加泼尼松联用硫唑嘌呤和大剂量IVIG,治疗1个疗程后评价心功能,检测治疗前后左房横径(LA)、左室舒张期内径(LV)、左室射血分数(LVEF)、心脏指数(CI),并计算其治疗前后变化。所有病例随访1年,计算1年存活率。结果治疗Ⅱ组心功能明显优于治疗Ⅰ组(P均<0.05);两组LA、LV、LVEF和CI治疗后较治疗前均有明显改善(P均<0.05);治疗Ⅰ组各参数变化明显低于治疗Ⅱ组(P均<0.05),其1年存活率明显低于治疗组Ⅱ(P<0.05)。结论泼尼松联用硫唑嘌呤和大剂量IVIG均能改善DCM患儿心功能,但IVIG疗效优于泼尼松联用硫唑嘌呤。 相似文献